Skip to main content
NYRADA INC. logo

NYRADA INC. — Investor Relations & Filings

Ticker · NYR ISIN · AU0000070195 ASX Professional, scientific and technical activities
Open in API
Filings indexed 472 across all filing types
Latest filing 2025-08-12 Share Issue/Capital Cha…
Country AU Australia
Listing ASX NYR

About NYRADA INC.

https://www.nyrada.com

Nyrada Inc. specializes in the development of novel small molecule therapeutic agents designed to address unmet needs in cardiovascular health and neuroprotection. The company’s lead programs include a cholesterol-lowering treatment and a neuroprotective treatment for brain injury. The cardiovascular program focuses on an oral PCSK9 inhibitor aimed at managing low-density lipoprotein (LDL) cholesterol levels as an alternative to injectable biologics. The neuroprotection program involves the development of NYR-BI03, a first-in-class small molecule designed to mitigate secondary brain damage following a stroke or traumatic brain injury by targeting canonical transient receptor potential (TRPC) ion channels. These efforts aim to provide effective, accessible pharmacological interventions for both chronic metabolic conditions and acute neurological trauma.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - NYR 6 pages 18.2KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an announcement from NYRADA INC. regarding the application for quotation of securities on the ASX. It details the securities issued as a result of options being exercised or convertible securities being converted, including the number of securities, issue dates, and other related information. The document is an official notice related to the listing or quotation of securities rather than a financial report, earnings release, or management discussion. This type of document corresponds to announcements about share issues or capital changes, specifically the application for quotation of new securities. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length is 5780 characters, which is sufficient to contain substantive details, confirming it is not merely a brief announcement or report publication notice.
2025-08-12 English
Cleansing Statement 2 pages 254.1KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Cleansing Statement' and announces the issue of 150,000 CHESS Depositary Interests (CDIs) related to options exercised. It references compliance with sections of the Corporations Act 2001 (Cth) and provides legal assurances about disclosure obligations. The document is short (3277 characters) and primarily serves as a regulatory notice about a capital issuance event without detailed financial data or analysis. It does not contain financial statements or management discussion, nor is it a full report or earnings release. The content aligns with announcements about capital structure changes or fundraising activities. Therefore, the document fits best under 'Capital/Financing Update' (CAP).
2025-08-12 English
Application for quotation of securities - NYR 6 pages 18.5KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an official announcement from NYRADA INC. regarding the application for quotation of securities on the ASX. It details the securities to be quoted, issue dates, and related information about the securities issued as part of a previously announced transaction (Appendix 3B). The document is a formal application for listing new securities rather than a report on financial performance, management, or other corporate activities. This fits the category of Share Issue/Capital Change announcements, which cover new share issues and related capital changes. The document length is about 5475 characters, and it is not a report itself but an announcement of a capital market action.
2025-08-10 English
Cleansing Statement 2 pages 238.6KB
Capital/Financing Update Classification · 95% confidence The document is a Cleansing Statement issued by Nyrada Inc. regarding the issue of 26,200,000 CHESS Depositary Interests (CDIs) as part of a Capital Raising Program. It references compliance with sections of the Corporations Act 2001 (Cth) and mentions that the CDIs were issued without disclosure under Part 6D.2 of the Corporations Act. The document is short (3328 characters) and primarily serves as a regulatory notice about a capital raising event rather than a detailed financial report or presentation. It does not contain financial statements or detailed analysis but is an announcement related to financing activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-08-10 English
BioShares Biotech Summit Presentation 12 pages 1.6MB
Investor Presentation Classification · 95% confidence The document is titled 'BioShares Biotech Summit Presentation' and is described as an investor presentation to be delivered by the CEO at a biotech summit. It contains detailed information about the company's drug development pipeline, preclinical study results, financial position, and future plans. The text includes forward-looking statements and disclaimers typical of investor presentations. There is no indication that this is a formal regulatory filing like an annual or interim report, audit report, or earnings release. The document is not a brief announcement or a certification but a detailed presentation aimed at investors. Therefore, the document fits the category of an Investor Presentation (IP). The document length (over 11,000 characters) and content support this classification with high confidence.
2025-08-05 English
Positive Final Review of Nyrada Phase I Clinical Trial 4 pages 269.9KB
Regulatory Filings Classification · 90% confidence The document is a detailed announcement about the positive final review of a Phase I clinical trial by Nyrada Inc. It discusses safety and pharmacokinetic data, trial cohorts, and future plans for Phase IIa trials. The content is focused on clinical trial results and development updates rather than financial performance, regulatory filings, or shareholder matters. There is no indication that this is an annual report, earnings release, or any financial report. It is also not a regulatory filing or certification. The document is a corporate announcement about clinical trial progress and results, which does not fit into the financial or governance categories. Given the nature of the content, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other specific categories.
2025-08-05 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.